Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation and Depletion: 2019-2024

Historic Depreciation and Depletion for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $4.8 million.

  • 4D Molecular Therapeutics' Depreciation and Depletion rose 8.33% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 4.08%. This contributed to the annual value of $4.8 million for FY2024, which is 9.09% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Depreciation and Depletion stood at $4.8 million, which was up 9.09% from $4.4 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Depreciation and Depletion ranged from a high of $4.8 million in FY2024 and a low of $1.4 million during FY2020.
  • Its 3-year average for Depreciation and Depletion is $3.9 million, with a median of $4.4 million in 2023.
  • Data for 4D Molecular Therapeutics' Depreciation and Depletion shows a peak YoY skyrocketed of 83.33% (in 2023) over the last 5 years.
  • Over the past 5 years, 4D Molecular Therapeutics' Depreciation and Depletion (Yearly) stood at $1.4 million in 2020, then increased by 7.14% to $1.5 million in 2021, then spiked by 60.00% to $2.4 million in 2022, then soared by 83.33% to $4.4 million in 2023, then climbed by 9.09% to $4.8 million in 2024.